Brought to you by 
Cambridge Epigenetix licenses DNA methylation IP from Boston Children's Hospital
01 May 2017
Executive Summary
Boston Children’s Hospital granted Cambridge Epigenetix Ltd. exclusive rights to IP surrounding the diagnostic applications of 5-hydroxymethylcytosine (5hmC) and the ten-eleven translocation (TET) family of enzymes.
Deal Industry
- Biotechnology
- In Vitro Diagnostics
- Research, Analytical Equipment & Supplies
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cambridge Epigenetix licenses DNA methylation IP from Boston Children's Hospital
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice